Drug Database
BE

bevacizumab (Abevmy / bevacizumab, Biocon / Krabeva)

✓ Approved

Mylan · VEGFA · Monoclonal Antibodies

What is bevacizumab?

bevacizumab is a monoclonal antibodies developed by Mylan. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesAbevmy, bevacizumab, Biocon, Krabeva
CompanyMylan
Drug ClassMonoclonal Antibodies, Antibody
Molecular TargetVEGFA
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Mylan

Mechanism of Action

Molecular Targets

bevacizumab acts on 1 molecular target:

VEGFAvascular endothelial growth factor A (VPF, MVCD1)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

bevacizumab is developed for 9 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer stage IV✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer metastatic✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Brain neoplasm malignant✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Fallopian tube cancer✓ Approved

+4 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedMedicine2026-07-25

Efficacy and prognostic factors of first-line bevacizumab plus chemotherapy in elderly patients with advanced driver gene-negative lung adenocarcinoma: A retrospective study.

Li Shuiyao S, Wang Shaojun S, Cao Ranhua R

We aimed to evaluate clinical outcomes and identify prognostic indicators in elderly patients with driver gene-negative advanced lung adenocarcinoma treated with first-line bevacizumab-based therapy. Elderly patients (≥65 years) with driver gene-negative advanced lung adenocarcinoma treated between January 2020 and December 2024 were retrospectively included. According to first-line treatment strategies, patients were divided into a chemotherapy-alone group and a bevacizumab plus chemotherapy group. Progression-free survival (PFS) and overall survival (OS) were analyzed using univariate and multivariate Cox regression models. A total of 169 patients were included. In the bevacizumab group, the median OS was 47 months and the median PFS was 24 months. Multivariate analysis showed that prognostic nutritional index (PNI), vascular endothelial growth factor A, carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA-125), and bevacizumab treatment were independent prognostic factors for PFS. Additionally, neutrophil-to-white blood cell ratio (NWR), neutrophil-to-lymphocyte ratio, PNI, vascular endothelial growth factor A, CA-125, and bevacizumab treatment were independently associated with OS. Our findings suggest that bevacizumab combined with chemotherapy is associated with favorable survival outcomes in elderly patients with driver gene-negative advanced lung adenocarcinoma. Inflammation-, nutrition-, and tumor burden-related biomarkers may help predict survival and assist in risk stratification.

PMID 42499069
Read full article →
PubMedGynecologic oncology reports2026-07-25

Durable response to pembrolizumab plus axitinib in platinum-resistant ovarian clear cell carcinoma: A case report.

Patel Nikhil S NS, Cook Joshua J JJ, Valcana Danielle E DE, Poiesz Michael J MJ et al.

Ovarian clear cell carcinoma (OCCC) is a rare and aggressive histologic subtype of epithelial ovarian cancer characterized by intrinsic chemoresistance and limited treatment options in the platinum-resistant setting. Immune checkpoint inhibitors and VEGFR-targeted therapies have demonstrated synergistic activity across multiple malignancies, though their role in OCCC remains incompletely defined. Axitinib is a selective VEGFR1-3 tyrosine kinase inhibitor approved for renal cell carcinoma but not OCCC. We report a 39-year-old female with FIGO stage IVA platinum-resistant OCCC who achieved durable disease control with pembrolizumab plus axitinib, despite prior mixed response to first-line therapies including bevacizumab. Tumor profiling demonstrated microsatellite stability, low tumor mutational burden, PD-L1 expression (TPS 5%), ARID1A mutation, and TP53 alteration. Serial imaging demonstrated sustained radiographic improvement followed by imaging findings suspicious for disease progression after approximately 23 months of disease control. This case highlights the potential therapeutic relevance of VEGFR inhibition combined with immune checkpoint blockade in platinum-resistant OCCC. In a setting with limited effective options, this combination strategy may provide meaningful clinical benefit in selected patients.

PMID 42500113
Read full article →
PubMedBulletin du cancer2026-07-24

Use of bevacizumab to treat glioblastoma in France: Regional practices in PACA and Corsica show a real therapeutic need.

Felker Gwendoline G, Rebroin Marina M, Beauger Davy D, Honoré Stéphane S

Glioblastomas, the most common and aggressive brain tumors in adults, present a significant therapeutic challenge. Despite the limited treatment options outlined by current guidelines, bevacizumab has emerged as a critical, yet controversial option. This study investigates the off-label use of bevacizumab in France, highlighting its therapeutic demand despite the absence of marketing authorization. Since the European Medicines Agency (EMA) rejected its application for glioblastoma treatment in 2009, it has not been re-evaluated at the European level. This research primarily aims to explore clinical practices surrounding bevacizumab's use and assess its relevance and potential benefits for patients with glioblastoma in real-world settings. A cross-sectional, observational epidemiological survey was conducted using data from ScanSanté® and feedback from hospitals in the Provence-Alpes-Côte d'Azur (PACA) and Corsica regions. These findings were then compared to literature data. In 2023, bevacizumab was used in 97.3% of hospital days related to malignant brain tumors treated off-label in France. Among off-label prescriptions for glioblastomas, 82.0% were for recurrent glioblastomas, 13.1% for newly diagnosed glioblastomas, and 4.9% had no precise diagnosis. Literature reviews indicate a favorable benefit-risk balance for certain patient profiles, particularly showing improved progression-free survival and quality of life when bevacizumab is employed. The significant off-label use of bevacizumab in glioblastoma treatment underscores an urgent therapeutic need in France. These findings were submitted to the French National Agency for the Safety of Medicines and Health Products (ANSM) to advocate for its regulated use in clinical practice.

PMID 42493295
Read full article →
PubMedJournal of neuro-oncology2026-07-24

Salvage therapies for recurrent grade 4 IDH-wildtype glioma: a BRAIN Registry analysis of real-world treatment patterns.

Sanderson Emma E, Drummond Katharine K, Dowling Anthony A, Bennett Iwan I et al.

The prognosis for patients with glioblastoma after failure of first-line therapy is poor. Despite this, the standard of care for patients with recurrent disease is not well-defined. Here we report on the use of salvage therapies in glioblastoma using real-world data. Data were extracted from the BRAIN Registry for patients diagnosed with glioblastoma (Grade 4, IDH wild-type) between 09/2019 and 01/2024. Only patients who received salvage therapies following a documented date of recurrence/progression were included. Relevant descriptive and intergroup statistics were used, with survival calculated using Kaplan-Meier and Cox regression used for multivariate analyses. 275 patients were identified. Median age was 61 (range:23-88) years, with 56% being ECOG 0-1 at recurrence. Median time to progression was 7.6 months with 65% recurring/progressing during first-line therapy. Systemic therapy (85%) was most utilised with 67% receiving single-agent bevacizumab. Outcomes in this subgroup were similar to clinical trial data. 29% patients underwent re-resection with 58% of these then receiving systemic treatment. Compared with no surgery, patients who underwent re-resection were younger (p = 0.02), of better performance status (p = 0.006) and more likely to have recurred post completing first-line therapy (p = 0.001). Few patients (n = 9) received re-irradiation with median of 15 months between radiation events. Median post-progression survival (PPS) was 9.5 months. After adjustment for confounders, there was no difference in PPS for patients who underwent re-resection versus systemic therapy alone (p = 0.242). The survival differences observed between treatment modalities likely reflect patient factors influencing treatment selection and were impacted by small subgroup sizes. Systemic therapy is most utilised in the salvage setting, predominantly bevacizumab. Certain patient characteristics were associated with re-resection. Re-irradiation was rarely used. ACTRN12618001959268.

PMID 42493681
Read full article →
PubMedFrontiers in medicine2026-07-24

Combined treatment using repurposed synthetic peptide desmopressin and bevacizumab as a potential antiangiogenic strategy in osteosarcoma.

Solernó Luisina María LM, Llavona Candela C, Saud Zahira Yasmine ZY, Onassis Mariana Carolina MC et al.

Osteosarcoma (OSA) is the most common primary malignant bone tumor and is characterized by high mortality, early metastatic dissemination, and extensive vascularization. Although overexpression of Vascular Endothelial Growth Factor A (VEGF-A) is associated with poor prognosis, clinical responses to the anti-VEGF-A monoclonal antibody Bevacizumab (BEVA) have been limited. Desmopressin (dDAVP), a hemostatic agent that acts as a selective arginine vasopressin receptor 2 (AVPR2) agonist, has demonstrated antitumor and angiostatic properties in other malignancies, however, its role in OSA remains incompletely characterized. This study evaluated the therapeutic potential of dDAVP as a coadjuvant strategy to enhance BEVA efficacy in OSA. Bioinformatic analyses of AVPR2 expression and its associations with tumor aggressiveness, immune and stromal infiltration markers, and clinical outcomes were performed using TCGA-SARC and TARGET-OS datasets. Endothelial proliferation, migration, and morphogenesis were assessed in HmVEC-L and HMEC-1 microvascular cells. Antitumor activity was evaluated in human (MG-63) and murine (K7M3) OSA models. In vivo activity was assessed using xenogeneic and syngeneic models of tumor growth, metastasis, and tumor-associated angiogenesis. Combined dDAVP + BEVA therapy was evaluated in vitro and in vivo. Histopathological endpoints included mitotic index, desmoplasia, vimentin expression, and tumor necrosis. Exploratory transcriptomic analyses revealed that AVPR2 expression was inversely associated with proangiogenic, prosurvival, and prometastatic gene signatures, while positively correlating with immune and stromal infiltration markers. Elevated AVPR2 expression was also associated with improved survival in both the pan-sarcoma cohort and a pediatric OSA subset. dDAVP significantly reduced pulmonary metastasis and OSA-driven vascularization in vivo and inhibited endothelial proliferation, migration, and morphogenesis in vitro. Under tumor-conditioned conditions, dDAVP enhanced the antivascular activity of BEVA. Combined treatment with clinically relevant doses of dDAVP and BEVA significantly inhibited OSA xenograft progression without overt toxicity and favorably modulated histopathological markers of tumor aggressiveness. These findings support further translational evaluation of dDAVP as a potential adjuvant therapy in OSA, particularly in combination with BEVA. By targeting complementary angiogenesis-related mechanisms, this dual antiangiogenic strategy may improve therapeutic efficacy in OSA.

PMID 42494441
Read full article →
PubMedLiver cancer2026-07-24

Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study.

Ueno Masayuki M, Su Yung-Yeh YY, Takai Atsushi A, Huang Yi-Hsiang YH et al.

Atezolizumab plus bevacizumab (Atezo+Bev) is the most widely used first-line treatment for unresectable hepatocellular carcinoma (HCC), while lenvatinib remains a standard alternative. Previous studies suggest limited efficacy of Atezo+Bev in patients with HCC exhibiting a CRAFITY score of 2 (CRP ≥1 mg/dL and AFP ≥100 ng/mL). We conducted an international collaborative study to compare the efficacy of Atezo+Bev and lenvatinib stratified by the baseline CRAFITY score. We retrospectively analyzed 994 patients who initiated Atezo+Bev or lenvatinib as first-line therapy for unresectable HCC between September 2017 and March 2024 across 11 hospitals in Japan and 13 hospitals in Taiwan. Patients were categorized by baseline CRAFITY score, and progression-free survival (PFS) and overall survival (OS) were compared between treatment groups. The median age of the patients was 71 years, and 770 (77.5%) were male. The baseline CRAFITY score was 0 in 375 patients (37.7%), 1 in 402 patients (40.4%), and 2 in 217 patients (21.8%). In patients with a CRAFITY-0 score, median PFS (10.8 vs. 9.4 months; p = 0.548) and OS (21.1 vs. 29.3 months; p = 0.074) did not differ significantly between Atezo+Bev and lenvatinib. Similar findings were observed in CRAFITY-1 patients, with median PFS of 6.0 vs. 6.1 months (p = 0.943) and OS of 12.7 vs. 15.1 months (p = 0.168). In contrast, among CRAFITY-2 patients, lenvatinib was associated with significantly longer PFS (2.3 vs. 4.4 months; hazard ratio, 0.66; p = 0.017), while OS did not differ significantly between treatments (5.7 vs. 9.1 months; hazard ratio, 0.90; p = 0.586). A significant interaction was observed between CRAFITY score (0/1 vs. 2) and treatment regimen (Atezo+Bev vs. lenvatinib) for PFS (p = 0.002). Consistent findings were observed in adjusted analyses. Lenvatinib was associated with significantly longer PFS than Atezo+Bev in patients with a baseline CRAFITY score of 2. The CRAFITY score may be useful for identifying patients in whom lenvatinib could be considered as a first-line option, and prospective validation is warranted.

PMID 42495656
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about bevacizumab